| Identification | Back Directory | [Name]
COLURACETAM | [CAS]
135463-81-9 | [Synonyms]
BCI-540
COLURACETAM
MKC-231;BCI-540
Coluracetam, >=99%
Coluracetam, MKC-231
COLURACETAM USP/EP/BP
top quality Coluracetam
MKC-231; MKC231; MKC 231
coluracetam cas: 135463-81-9
1-Pyrrolidineacetamide,2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)-
2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethyl-furo[2,3-b]quinolin-4-yl)-1-pyrrolidineacetamide
N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
1-[N-(2,3-DiMethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)carbaMoylMethyl]pyrrolidin-2-one | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C19H23N3O3 | [MDL Number]
MFCD00901416 | [MOL File]
135463-81-9.mol | [Molecular Weight]
341.4 |
| Chemical Properties | Back Directory | [Boiling point ]
634.1±55.0 °C(Predicted) | [density ]
1.291±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMF: 1 mg/ml; DMSO: 2 mg/ml; Ethanol: 2 mg/ml; PBS (pH 7.2): insol | [form ]
A crystalline solid | [pka]
12.01±0.20(Predicted) | [InChI]
InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23) | [InChIKey]
PSPGQHXMUKWNDI-UHFFFAOYSA-N | [SMILES]
N1(CC(NC2C3=C(N=C4OC(C)=C(C)C4=2)CCCC3)=O)CCCC1=O |
| Hazard Information | Back Directory | [Uses]
Copiracetam can be used as a nootropic drug to treat memory and intellectual impairments caused by senile dementia, mild to moderate vascular dementia, trauma and other diseases, and to promote children's intellectual development; it also has antidepressant effects. | [Pharmacology]
Copiracetam has the ability to improve cognition by participating in the HACU process, increasing the rate-limiting step of synaptic intake of choline to synthesize the neurotransmitter acetylcholine, and increasing the activity of cholinergic neurons. | [in vitro]
Coluracetam (10(-10)-10(-6) moll), also known as MKC-231, significantly increased high affinity choline uptake (HACU) when it was incubated with the hippocampal synaptosomes of ethylcholine mustard aziridinium ion (AF64A) treated rats, but not of normal rats. MKC-231 did not affect the AChE activity, [3H]- quinuclidinyl benzilate binding, and [3H]-pirenzepine binding.
| [in vivo]
Oral administration of MKC-231 (Coluracetam; 1-10 mg/kg) significantly improved the learning deficits in the Morris' water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine [1]. In acute behavioral experiments, MKC-231 and THA had no significant effect on AF64A-induced memory deficits at any doses tested (0.3, 1.0 and 3.0 mg/kg), whereas Dup 996, at a dose of 1.0 mg/kg, significantly improved memory deficits. In chronic experiments, MKC-231 improved memory deficit at all doses tested (0.3, 1.0, or 3.0 mg/kg p.o., once daily for 11 days) and Dup 996 did so only at a dose of 3.0 mg/kg, whereas THA did not improve memory deficit at any doses tested.
|
|
|